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new FIL agents will increase. If the California data reflect national trends, uptake 
may continue to be slow compared with more established biosimilar markets in 
Europe.
PCN346
FreNCh PhysiCiaN seNsitivity to aNd CoNsideratioN oF the Costs oF 
CaNCer treatmeNt
Chabernaud H, Flinois A, Bonnelye G
Kantar Health, Montrouge, France
Expenses for anticancer treatment in France have grown substantially with an aver-
age annual cost increase of 17.7% between 1999 and 2009. This is due to access to 
expensive targeted therapies, higher cancer incidence rates and overall survival in 
patients with advanced disease.Objectives: To evaluate physician opinions and 
attitudes and their evolution between 2003 and 2013 regarding the costs of anti-
cancer treatments MethOds: Conducted in France biennially, the « Cancérologie » 
study measures physician opinions/attitudes on today’s relevant topics. Latest 
waves of this study included a series of questions on the cost of anticancer treat-
ments, allowing for analysis of the evolution of responses. In 2013 315 physicians 
who work in French public or private hospitals and prescribe antitumor treatments 
for solid and/or liquid cancer participate to the study. Results: In 2003, 54% of phy-
sicians considered cancer related budgetary issues ‘very important’. Over the years, 
this percentage progressively decreased until dropping to 25% in 2013. However, in 
2003, 68% predicted that the budgetary situation would deteriorate further com-
pared with 73% in 2013. The contrast between the pessimistic perceptions of the 
future and a reality which is perceived less and less problematic demonstrates the 
dual mindset of physicians who are at once: - Citizens conscious of how the growth 
of costs can only end in an impasse, - Clinicians whose prescriptions remain guided 
by therapeutic goals. Thus in 2013, 62% of physicians indicated that costs had little to 
no impact on their choice of treatment. cOnclusiOns: New molecule availability 
will cause costs of anticancer therapies to continue to grow at the same rate seen in 
recent years. If physicians do not take greater responsibility for their prescriptions’ 
costs, the only solution would be coercive measures.
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Objectives: In 2013, it was shown that mutations in KRAS exons 3 and 4, or NRAS 
exons 2 to 4 had a similar effect. The primary objective was to assess the practices 
in conducting RAS testing in 2014. The secondary objectives were to describe the 
evolution of the RAS testing prescription rates from 2011, the process and time 
required to obtain the results, and to analyze their impact on the therapeutic strat-
egy. MethOds: FLASH-RAS is an observational retrospective French multicenter 
study. Results: 375 mCRC patients diagnosed and initiating a 1st line treat-
ment (L1) between March and June 2014 were analyzed. For 90.1% of the patients 
(IC95%= [87.1%; 93.2%]), a genotyping request for RAS biomarkers was made in L1, 
i.e. a significantly increased rate compared to 2011 (81.1% in 2011, p< 0.001). For 75% 
of the patients, the request was made before or at least one month after the diagno-
sis of the first metastases (1st M). No increase was observed in the median and mean 
times to obtain the test results between 2011 and 2014 despite the increased number 
of exons tested. cOnclusiOns: In 2014, the rate of RAS genotyping requests has 
been increasing since 2011. For a majority of patients, the request is made before 
or at the latest one month after 1st M diagnosis. Nevertheless, for 24.5% of the 
patients, the request is made more than one month after 1st M diagnosis, which is 
not compatible with an informed treatment decision in L1.
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Objectives: The Chronic Care Model (CCM) is an accepted framework for deliv-
ering care to patients with chronic illnesses. The Patient Assessment of Chronic 
Illness Care (PACIC) is a questionnaire designed to assess the CCM from the 
patient´s perspective, focusing on the receipt of patient centered care. Our aim 
was to document patient´s assessment of chronic illness care in short-term cancer 
survivors, through PACIC MethOds: Patients with colo-rectal (CCR), breast or 
prostate cancer and who finished their treatment three years before answering 
the questionnaire were included in the study. PACIC was administered by mail 
and has 5 subscales, patient activation (PA), delivery system design (DSD), goal 
setting (GS), problem solving (PS) and follow-up coordination (FU). In addition 
there is a global score (G). Each subscale and the global are scored from 1 to 
5 with higher scores indicating patient´s perception of greater involvement in 
self- management and receipt of chronic care counseling. Data are expressed as 
mean (standard deviation). Comparison amongst location has been carried out 
through analysis of variance with Scheffé post-hoc test. PACIC has been validated 
in Spanish. Results: There were 645 patients included, 139 prostate, 339 breast 
and 167 with CCR. The mean (SD) by dimensions were: PA: 3.2 (1.4), DSD: 3.5 (1.2), 
GS: 2.6 (1.3), PS: 2.8 (1.5), FU: 2.2 (1.2) and global: 2.8 (1.2). There were statistically 
significant differences amongst cancer location in two dimensions, PS (p= 0.02) 
and FU (p = 0.002), with best scores in CCR in both cases. cOnclusiOns: To our 
knowledge this is the first time that PACIC is used in cancer patients. Patient 
activation and delivery system design have shown the best scores and follow-up, 
a critical point the worst score although with differences; being CCR survivors 
who better have evaluated this dimension
prevalence data for 6 cancers with values ranging from < 3 to > 170 per 105were 
obtained from the GLOBOCAN database. Clinicaltrials.gov was searched for phase 3 
trials for the cancers from 2005 to 2015; the NICE website was searched for technol-
ogy appraisals concerning the cancers for the same period. Results: Breast cancer 
(BC; prevalence, 174.1 per 105) had the greatest number of phase 3 clinical trials 
(n= 333) and NICE assessments (n= 10) in the period; three assessments resulted in 
recommendations. Prostate cancer (PC), having a similar prevalence to BC (162.5 per 
105), had 60% fewer phase 3 trials (n= 133) and 50% fewer NICE assessments (n= 5), 
but also resulted in three recommendations. Multiple myeloma (MM; prevalence, 
6.2 per 105) was the subject of a disproportionately high number of phase 3 trials 
(n= 98) and NICE assessments (n= 4); three assessments resulted in recommenda-
tions. In contrast, non-Hodgkin’s lymphoma, having a higher prevalence than MM 
(15.4 per 105) was the subject of only 40 phase 3 trials and 4 NICE assessments; three 
resulted in recommendations. Myelofibrosis and pancreatic cancer, each having a 
prevalence of < 5 per 105, were the subject of 11 and 25 phase 3 trials, respectively. 
One NICE assessment was performed for an intervention for myelofibrosis and had 
a negative outcome. cOnclusiOns: These results suggest that while the number 
of NICE assessments undertaken reflects the number of phase 3 trials performed 
in a given cancer, there is a mismatch between the number of assessments and the 
prevalence of specific cancers in the UK. Further research is warranted to investigate 
whether a similar mismatch is evident in other countries.
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Objectives: The Dutch minister of health made reimbursement of the first new 
melanoma drug conditional on the set-up of a population-based registry and cen-
tralisation of care. This led in 2012 to well-defined quality standards and the Dutch 
Melanoma Treatment Registry (DMTR) characterised by its unique collaboration 
between all stakeholders involved in melanoma care (public and private partner-
ship). The DMTR aims to enhance real patient value by closing the gap of the 
initial uncertainty regarding the real-world value of promising drugs in everyday 
practice. MethOds: The DMTR prospectively documents detailed data of all Dutch 
advanced melanoma patients regarding tumour- and patient characteristics, treat-
ment strategies, clinical, physical, social, emotional and well-being outcomes, 
resource use, informal care, and productivity losses. These data are used for bench-
marking and outcomes research to obtain insights into real-world cost-effective-
ness of treatment pathways to improve health decision making. Results: The 
richness of DMTR data facilitates the assessment of multiple outcomes includ-
ing quality of care, use of drugs, survival benefit, quality of life, costs and cost-
effectiveness. Physicians are fortnightly provided with feedback on their delivered 
quality of care; manufacturers are provided with information regarding the use 
and performance of their drugs. This greatly enhances learning regarding the 
use and outcomes of treatments. First results (stage IV: N= 1226; median follow-
up 12.8 months) show an improved survival (2012-2015: median OS 9.3 months 
[IQR:4.5-17.4], one-year survival rate 40%) compared to the period before the 
introduction of the new drugs (2003-2011: median OS 6.8 months [IQR:3.3-18.5], 
one-year survival rate 33%). cOnclusiOns: The DMTR provides crucial informa-
tion regarding the extent to which novel treatments offer real-world value and 
whether scarce resources are spent cost-effectively in everyday practice. Its unique 
design emphasises the essential holistic view needed in cancer management and 
can be seen as blueprint for other registries aiming at improving health decision 
making.
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Objectives: Biosimilars of filgrastim (FIL), granulocyte colony-stimulating factor 
(G-CSF), have been available in Europe since 2008. Now 2 FIL products are approved 
in the USA: tbo-filgrastim (TBO-FIL, while a biosimilar in Europe, is not techni-
cally one in the USA; approved November 2013 for a subset of FIL indications) and 
filgrastim-sndz (FIL-SNDZ, the first true US biosimilar; approved March 2015, but 
launch delayed by ongoing litigation). Our objective was to identify physician docu-
mentation and use of TBO-FIL during patient office visits. MethOds: Physician 
records were extracted (1 November 2013‒18 June 2015) from RealHealthData, a 
US medical transcription database providing data within 72 hours of each visit 
to a participating provider. Records were searched for mention of TBO-FIL: “tbo-
filgrastim,” “Granix,” or “Neutroval.” Mentions of FIL (“filgrastim” or “Neupogen”) 
and PEG (“pegfilgrastim” or “Neulasta”) were also tabulated. Results: Counts 
of mentions (and number of unique prescribers) were as follows: PEG: 1864 (40); 
FIL: 431 (53); TBO-FIL: 5 (3), with > 86% from oncologists in California. TBO-FIL 
was reported, as “Granix,” for 4 patients. Prophylactic TBO-FIL was prescribed 
for 1 chemotherapy patient and as interim treatment for 2 patients with chemo-
therapy who normally received PEG. 1 patient reported taking TBO-FIL as needed 
for neutropenia symptoms. Only 1 of the 4 received TBO-FIL as their main G-CSF 
treatment. Counts will be refreshed in October 2015 and will include FIL-SNDZ 
data, if launched and available. cOnclusiOns: Among 2300 records reporting a 
G-CSF in this snapshot of primarily Californian oncologists, only 5 mentions of 
TBO-FIL were noted in the 18 months since launch. As awareness of ‘biosimilars’ 
improves in the USA and legal barriers are overcome, it is expected that uptake of 
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fees under the routine continuous chemotherapies were RMB11,333 (USD1,828) per 
patient, with 34.8% (RMB3,939) born by the patient out-of-pocket. Under PAP, for the 
same patient group, the patients monthly self-paid RMB4,519 (USD729) of the aver-
age fees for Icotinib and another RMB1,064 (USD172, 16.9% of total fees) for other 
drugs and routine treatment. cOnclusiOns: The PAP, which provides the targeted 
patients the access to innovative medicines with better efficacy and safety, greatly 
decreased the fees on routine treatment, but also brought additional self-paid cost 
on PAP-covered medicines. Further researches are needed to help decision makers 
to make the tradeoff among better accessibility, increasing cost and improved out-
comes from the clinical utilization of PAP-covered innovative medicines.
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mediCal reCord review
Kurosky S1, Mitra D2, Zanotti G2, Kaye JA3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Pfizer, Inc., New York, NY, USA, 3RTI 
Health Solutions, Waltham, MA, USA
Objectives: To describe demographic and clinical characteristics and real-world 
treatment patterns for post-menopausal patients with ER+/HER2- metastatic breast 
cancer (MBC) in the United Kingdom (UK). MethOds: We conducted a retrospective 
review of medical records from institutions across the UK. Records were eligible for 
abstraction if patients were post-menopausal, had ER+/HER2- MBC (stage IV), and 
had discontinued second-line treatment in the metastatic setting between 1/1/2008 
and 3/1/2014. Patients who participated in clinical trials were excluded. This study 
was considered a “Service Evaluation” by National Research Ethical Service guid-
ance, thus ethics review was not required. Patient demographic, clinical character-
istics and treatment patterns including time to progression (TTP) and treatment 
discontinuation were assessed. Results: Forty-one medical/ clinical oncologists 
provided information for 209 patients. Patients were aged 62 years on average and 
predominantly Caucasian (87%), with 68% diagnosed in metastatic stage and 32% 
progressed from earlier stages. Bone was the most common site of metastasis (66%) 
followed by lung/pleura (50%), liver (41%), and lymph nodes (35%). In the first-line 
MBC setting, 49% of patients received endocrine therapy alone, 6% received it in 
combination with chemotherapy, 15% received it following chemotherapy induction, 
and 30% received chemotherapy alone. Chemotherapy usage increased in subse-
quent therapy lines (33% in second-line [n= 209]; 53% in third-line [n= 116]). Disease 
progression was the primary reason for discontinuing treatment in both first- and 
second-line (60% and 68% respectively). During first-line treatment, 86% progressed, 
with median TTP of 9.5 months. In second-line, 79% progressed, with median TTP of 
7 months. cOnclusiOns: Endocrine therapy and chemotherapy were commonly 
prescribed for ER+/HER2- MBC patients. Disease progression remains the most com-
mon reason for stopping/ changing therapies, with median TTP < 1 year. These 
findings suggest that there is a continuing unmet need for new treatments that can 
extend TTP and address the potential limitations of current therapies.
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Objectives: To describe the real-world treatment patterns of current melanoma 
therapies among patients with metastatic melanoma in the US. MethOds: A ret-
rospective cohort analysis was conducted using the IMS PharMetrics Plus claims 
database. Patients were included in the analysis if: ≥ 1 prescription for ipilimumab, 
vemurafenib, temozolomide, or dacarbazine between 1/1/2011-8/31/2013 (the date 
of the first use as the index date and the drug as the index drug); diagnosis of 
melanoma (ICD-9-CM 172.x, V10.82) and metastasis (ICD-9-CM 196.x-198.x) before 
the index date (pre-index); no index drug use pre-index date; continuous health 
plan enrollment for ≥ 6 months before and ≥ 3 months after the index date; age ≥ 18 
years. Treatment duration was assessed from the index date until a gap in days 
supplied for > 90 days, or the end of follow-up, whichever came first. Proportion 
of days covered (PDC) was defined as days exposed to the index therapy divided 
by continuously-enrolled days between the index date and the last prescription 
date of the index drug. Results: 1,043 patients with metastatic melanoma were 
included, with a median age of 57 years (43% ≤ 55 years), and 62% male. 405 patients 
received the index drug of ipilimumab, 361 vemurafenib, 203 temozolomide, and 
74 dacarbazine. Mean (median) treatment duration with vemurafenib, temozolo-
mide and dacarbazine was 174 (148), 100 (59) and 64 (52) days, respectively. Mean 
PDC with vemurafenib, temozolomide and dacarbazine was 81%, 67% and 51%, 
respectively. For patients receiving ipilimumab, 58% (234/405) had the full 4 doses, 
20% (79/405) had 3 doses only, 14% (57/405) had 2 doses only, and 9% (35/405) had 1 
dose only for the first treatment course; 4% (10/234) received re-treatment, and no 
patients had a second re-treatment. cOnclusiOns: This study provides evidence 
of current treatment patterns of melanoma therapies, including newer agents, in 
the real-world clinical practice.
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Objectives: To characterize real-world treatment patterns among front-
line patients with glioblastoma in Germany, France, Italy, UK, and Spain (EU-
5). MethOds: This study used the oncologist-surveyed data from the IMS LifeLink™ 
Oncology Analyzer database. Front-line patients aged ≥ 20 years and diagnosed 
with glioblastoma during 2012 to 2014 in the EU-5 countries were included. Patient 
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Objectives: To evaluate the economic results of this PbR compared to a traditional 
purchasing model and determine the perception of the stakeholders involved in 
the agreement. In healthcare systems, incentive-based schemes generally called 
payment-by-results schemes (PbR), which dynamically link the price of innovation 
to the usage conditions are alternatives to traditional fixed payment schemes. 
In 2011, the first PbR in Catalonia was signed between the Catalan Institute of 
Oncology, the Catalan Health Service and AstraZeneca (AZ) for the introduction 
of gefitinib in the treatment of EGFR-mutation positive advanced non-small-cell 
lung cancer. MethOds: Economic analysis of the differential costs between two 
scenarios, one including the total cost of treatment and the PbR scenario where 
AZ reimbursed the treatment according to previously agreed terms. 41 patients 
were included from June 2011 to October 2013 and assessed at two evaluation 
points. At week 8, responses, stabilization and progression were evaluated and 
at week 16 stabilization was confirmed. AZ was to reimburse the total cost of 
treatment of those patients that failed the treatment. A qualitative research of 
the organizational elements was done by interviewing the parties involved in the 
contract Results: The difference in cost of gefinitib using the PbR compared to 
the traditional purchasing scenario was 6.17% less at 8 weeks, 11.18% at 16 weeks 
and 4.15% less for the overall treatment. The PbR resulted in total savings of around 
€ 36,000, which corresponds to approximately € 1,000 per patient. From an opera-
tional and organizational perspective, the availability of adequate information 
systems to measure outcomes and monitor accountability and the involvement of 
healthcare professionals were acknowledged as crucial. cOnclusiOns: The par-
ties have identified tangible and intangible benefits with respect to the interests 
of the parties involved. This has led to the incorporation of innovation for patients 
under acceptable conditions.
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Objectives: Risk-sharing scheme (RSS) has been implemented since Nov 2013 
as part of policies to increase patients’ accessibility in Korea. This study aimed 
to compare the impact of reimbursement rate before and after the implementa-
tion of RSS especially in anticancer drugs and to review the characteristics of the 
anticancer drugs on risk-sharing agreement (RSA). MethOds: Reviewed appraisal 
results for anticancer drugs in HIRA Drug Reimbursement Assessment Committee 
from 2007 to Jun 2015. The rate of reimbursement recommendation before and after 
RSS implementation and the proportion of RSA after RSS implementation were 
assessed. Drugs recommended after RSS implementation were classified into com-
parative clinical effectiveness-superior, non-inferior, similar- and cost effectiveness-
assessed by economic analysis or weighted average price. From each category, the 
proportion of RSA drug and type of scheme were counted. Results: During 8.5 
years, total 86 appraisals of anticancer drugs, the reimbursement recommendation 
rate was 58.1%(50/86). The reimbursement recommendation rate was 55.4%(31/56) 
before RSS implementation and 63.3%(19/30) after RSS implementation. After RSS 
implementation, 19 appraisals of anticancer drugs were reimbursement, 10 of them 
were reimbursement on the condition of RSA (53%), and types of RSS were refund 
(100%). As for comparative clinical effectiveness of among 19 appraisals after RSS 
implementation, 16 were superior, 3 were silimilar to comparator. Among ‘superior’ 
group, 12 were assessed by economic analysis (CUA), 6 of them were on RSA (50%). 
The number of appraisals not assessed by economic analysis in superior group was 
4, and they were on RSA. In ‘similar’ group, all were assessed by weighted average 
price and none of them were on RSA. cOnclusiOns: The implementation of RSS 
seemed to contribute to increase patients’ accessibility to new anticancer drugs. RSS 
can be a compensating way to decision-making for reimbursement of anticancer 
drugs which are clinically beneficial but having uncertainty in cost-effectiveness.
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Objectives: A patient access program (PAP) was adopted by local health insur-
ance scheme in Qingdao since 2012 to provide the coverage of innovative products 
for catastrophic diseases including non-small cell lung cancer. This study aims to 
measure the impact of PAP on economic burden of the patients with non-small cell 
lung cancer. MethOds: The patients with non-small cell lung cancer during 2008 
and 2013 were identified from health insurance information system. All claims data, 
including total treatment fees, the composition and the out-of-pocket fees born by 
the patients, were collected and a comparative analysis before and after the PAP 
implementation was conducted. Results: The PAP was achieved through price 
negotiation between local health insurance agent and manufacturers and reim-
bursed 70% of the cost of PAP-covered innovative medicines including Icotinib for 
non-small cell lung cancer. Totally 299 new patients with non-small cell lung cancer 
registered in PAP and another 78 patients were identified to switch from routine 
chemotherapies into Icotinib regimen. Before PAP, the average monthly treatment 
